6120 RESULTS
Sort By:
RESEARCH NEWS 2002-11-19 Research News Embryonic stem (ES) cells have the inherent potential to replace or repair almost every tissue in the body. One key to this prowess is the ability to migrate, without which ES cells could not travel to the sites where they are needed. While
RESEARCH NEWS 2002-11-18 Research News Insulin resistance is emerging as a possible risk factor for Alzheimer’s, and data from a pilot trial presented at the 2002 Neuroscience meeting indicate that an insulin-sensitizing drug may represent a novel treatment approach. Suzanne Craf
RESEARCH NEWS 2002-11-18 Research News Assays of Aβ or tau protein in cerebrospinal fluid can identify Alzheimer's disease in patients with mild cognitive impairment, say the authors of a study in today’s Archives of Neurology. With a number of potential AD preventive measur
RESEARCH NEWS 2002-11-16 Research News In a transgenic mouse model of Alzheimer's amyloidosis, lesioning the perforant pathway from the entorhinal cortex (EC) to the hippocampus substantially reduces the amyloid burden of the hippocampus. This is the conclusion of two simila
RESEARCH NEWS 2002-11-15 Research News The replacement of dying neurons in Alzheimer’s disease with neural stem cells remains a pie in the sky, but at least researchers now appear to have gotten their hands on the filling. In the November 11 online Nature Neuroscience, investigat
RESEARCH NEWS 2002-11-14 Research News Aβ immunotherapists are back at the drawing board after inflammatory complications scuttled the first clinical trial (see Schenk, 2002). A short communication in tomorrow’s Science raises the spectre of another factor that researchers should
CONFERENCE COVERAGE 2002-11-12 Conference Coverage Preliminary results of the NGF gene therapy clinical trial in early-stage AD illustrate the potential promise-and pitfalls-of gene therapy for neurodegenerative diseases. Mark Tuszynski of the University of California, San Diego, prese
RESEARCH NEWS 2002-11-08 Research News Use of hormone replacement therapy (HRT) appears to protect some women from Alzheimer's disease, according to a prospective observational study of AD risk factors published in this week's JAMA. In particular, the study found that w
COMMUNITY NEWS 2002-11-06 Community News It may not be the Oscars or Nobel prize, but recipients of the second annual Alzheimer Research Forum Awards were warmly applauded during the Society for Neuroscience meeting's Alzheimer Disease Social. The Innovation Award was given t
CONFERENCE COVERAGE 2002-11-06 Conference Coverage In three posters on Wednesday here at the annual Neuroscience meeting, William Klein’s laboratory extended their earlier presentation (see related news story) to add new pieces to the puzzle of the amyloid cascade hypothesis. One study
CONFERENCE COVERAGE 2002-11-05 Conference Coverage In a sparsely attended slide presentation yesterday at the Neuroscience meeting, Inez Vincent of the University of Washington, Seattle, presented a feat no one seems to have pulled off before: With an experimental small-molecule compou
CONFERENCE COVERAGE 2002-11-05 Conference Coverage In the field’s current focus to understand what might go wrong at synapses early on in AD, measuring long-term potentiation has become a widely applied tool. This phenomenon of synaptic strengthening in response to intense stimulation
CONFERENCE COVERAGE 2002-11-04 Conference Coverage Today at the annual meeting of the Society for Neuroscience, Lee Goldstein of Massachusetts General Hospital presented evidence suggesting that the Aβ peptide occurs in the eyes of people with Alzheimer’s disease, raising the intriguin
CONFERENCE COVERAGE 2002-11-04 Conference Coverage Aβ levels and amyloid plaque load can be reduced significantly in animal models of Alzheimer's disease by interfering—either genetically or pharmacologically—with the immunoregulatory molecule CD40 ligand, according to a report in
CONFERENCE COVERAGE 2002-11-04 Conference Coverage Today at the Society for Neuroscience Conference, Ross Bland’s poster about a new rat model for the study of Alzheimer’s disease drew quite a crowd. Performed in the lab of Matthew During at Thomas Jefferson University in Philadelphia
